Mario Lemieux Foundation

What it reported doing in 2024

The foundation also supports blood cancer research in both the clinic and lab. In 2014, the foundation established the mario lemieux center lymphoma center for children and young adults at children's hospital of pittsburgh of upmc. This center, the first of its kind, treats patients with difficult-to-treat and rare childhood lymphomas. The center has increased access to care and cutting-edge treatments for all childhood lymphomas, while also bringing together a critical volume of patients with rare lymphomas for research studies that can have had a global impact on care. The annual commitment to this $2.5m project is $357,000. **see continuation on schedule o**the foundation also supports hodgkin's disease research and patient care by providing funding to the mario lemieux center for blood cancers, located at the upmc hillman cancer center. In november 2018, the mario lemieux foundation pledged additional support to the upmc hillman cancer center in a $5m gift for groundbreaking immunotherapy research and treatment. The mario lemieux immunotherapy center will expand and enhance innovative immunotherapy treatments for patients with certain types of solid tumors, both through research and personalized patient care. The immunotherapy center opening was delayed because of the covid 19 pandemic. However, the center for blood cancers remained open and served patients. In fy 22 the board committed $5m to upmc children's hospital of pittsburgh to establish the mario lemieux institute for pediatric cancer research. The opening was held in october 2023. This new institute focuses on supporting future research leaders who will help generate new scientific breakthroughs and cutting-edge clinical trials in pediatric cancer research and translate that research directly to patients.

Financial Efficiency

• Mission deployment rate: 32.9%; rating input score 33
• Program expense ratio: 55.3%; rating input score 55
• Fundraising efficiency: $11.39 raised per $1 spent on fundraising; rating input score 42; 42nd percentile among comparable filings

Transparency & Controls

• Consistency checks: 94.4%; rating input score 94; 24th percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Missing
  • Other Form 990s reviewed: Pass
  • Written employment contract: Pass
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 88.2%; rating input score 88; 25th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
• Governance controls: 8 of 8 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 60.9%; rating input score 95; 95th percentile among comparable filings
• Total-asset coverage ratio: 11.62; rating input score 92; 92nd percentile among comparable filings
• Liabilities to assets ratio: 0.3; rating input score 34; 34th percentile among comparable filings
• Officer compensation ratio: 18.8%; rating input score 14; 14th percentile among comparable filings

Growth

• Program expense growth: 2% per year; rating input score 100; 22nd percentile among comparable filings
• Revenue growth: 7.7% per year; rating input score 100; 58th percentile among comparable filings
• Asset growth: 11.1% per year; rating input score 100; 62nd percentile among comparable filings